Hardman & Co. Study on Shield Therapeutics (STX): Focus on Successful Execution

Focus on successful execution

Shield is a commercial-stage pharmaceutical company delivering specialty products that address the unmet medical need of patients with iron deficiency (ID). Since its launch in the US in July 2021, Shield and Viatris have been driving physician awareness of ACCRUFeR’s differentiating features as an oral ID drug, driving sales growth. 1H’24 results confirmed that sales remain strong, while costs are closely monitored. Management is focused on successful execution and has reaffirmed its view that gross cash position combined with expected growth will be sufficient to bring Shield to cash flow breakeven in 2H’25.

Click on the link below for the full report:

https://hardmanandco.com/research/corporate-research/focusing-on-succe…

If you are interested in meeting the company, you can register by clicking the link above.

Hardman & Co Research is freely accessible under MiFID. click here to read the statement.

About Hardman & Co: Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered with Companies House number 8256259. Please note the important disclaimers at the end of the report.

Distribution of CORPORATE NEWS, broadcast by EQS Group.
The publisher is solely responsible for the content of this communication.

End of announcement – EQS News Service

1986203 11-Sep-2024